このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Ekso Bionics Holdings マネジメント

マネジメント基準チェック /44

Ekso Bionics Holdings'の CEO はScott Davisで、 Dec2022年に任命され、の在任期間は 1.5年です。の年間総報酬は$ 637.02Kで、 58.9%給与と41.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.57%を直接所有しており、その価値は€ 96.91K 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と3年です。

主要情報

Scott Davis

最高経営責任者

US$637.0k

報酬総額

CEO給与比率	58.9%
CEO在任期間	1.8yrs
CEOの所有権	0.5%
経営陣の平均在職期間	2.5yrs
取締役会の平均在任期間	3.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Ekso Bionics Holdings の収益と比較して、Scott Davis の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$12m
Mar 31 2024	n/a	n/a	-US$14m
Dec 31 2023	US$637k	US$375k	-US$15m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$15m
Dec 31 2022	US$1m	US$370k	-US$15m

報酬と市場: Scottの総報酬 ($USD 637.02K ) は、 German市場 ($USD 496.69K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Scottの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Scott Davis (54 yo)

1.8yrs

在職期間

US$637,020

報酬

Mr. Scott G. Davis serves as Chief Executive Officer of Ekso Bionics Holdings, Inc. since December 04, 2022 and serves as Director since December 08, 2022, and also served as its President & Chief Operatin...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Scott Davis	CEO & Director	1.8yrs	US$637.02k	0.48% $ 98.5k
Jerome Wong	Chief Financial Officer	2.3yrs	US$726.08k	0.21% $ 42.7k
Jason Jones	Chief Operating Officer	1.8yrs	US$710.24k	0.22% $ 45.9k
Rachael Anderson	Global Director of Marketing & Strategic Growth	3.8yrs	データなし	データなし
Ann Cookson	Human Resources Director	2.5yrs	データなし	データなし
Foon Chwee	President of APAC	6.8yrs	データなし	データなし
Stephan Aderhold	Senior VP & GM of EMEA	2.8yrs	データなし	データなし

2.5yrs

平均在職期間

経験豊富な経営陣: 23E2の経営陣は経験豊富であると考えられます ( 2.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Scott Davis	CEO & Director	1.8yrs	US$637.02k	0.48% $ 98.5k
Sherri Medina	Member of Advisory Council	no data	データなし	データなし
Hans Keirstead	Member of Advisory Council	no data	データなし	データなし
Mary Cloyd	Independent Director	3.8yrs	US$147.01k	0.66% $ 134.8k
Corinna Lathan	Lead Independent Director	2.8yrs	US$158.13k	0.69% $ 140.2k
Nancy Byl	Member of Advisory Council	no data	データなし	データなし
Tom Kelley	Member of Advisory Council	no data	データなし	データなし
Daniel Kraft	Member of Advisory Council	no data	US$72.21k	データなし
Kel Bergmann	Member of Advisory Council	no data	データなし	データなし
Graham Creasey	Member of Advisory Council	no data	データなし	データなし
Suzy Kim	Member of Advisory Council	no data	データなし	データなし
Charles Li	Independent Director	6.6yrs	US$143.10k	0.37% $ 75.0k

3.3yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: 23E2の取締役会は経験豊富であると考えられます ( 3年の平均在任期間)。

Ekso Bionics Holdings マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Executive Chairman of the Board recently sold €61k worth of stock

High number of new and inexperienced directors

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Recent updates

New major risk - Shareholder dilution

Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $5.9971 million.

Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

New major risk - Financial position

Forecast to breakeven in 2026

New minor risk - Profitability

Second quarter 2024 earnings released: US$0.13 loss per share (vs US$0.31 loss in 2Q 2023)

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Ekso Bionics Holdings, Inc. to Report Q2, 2024 Results on Jul 29, 2024

Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors

Forecast to breakeven in 2026

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.33 loss in 1Q 2023)

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Ekso Bionics Holdings, Inc. to Report Q1, 2024 Results on Apr 29, 2024

No longer forecast to breakeven

New minor risk - Profitability

Ekso Bionics Holdings, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Forecast to breakeven in 2026

Ekso Bionics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR

Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.33 loss in 3Q 2022)

Ekso Bionics Holdings, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Ekso Bionics Holdings, Inc. Receives Non-Compliance Notice from Nasdaq

New major risk - Financial position

Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.23 loss in 2Q 2022)

Ekso Bionics Holdings, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Executive Chairman of the Board recently sold €61k worth of stock

High number of new and inexperienced directors

No longer forecast to breakeven

Full year 2022 earnings released: US$1.16 loss per share (vs US$0.80 loss in FY 2021)

Forecast to breakeven in 2025

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million.

Third quarter 2022 earnings released: US$0.33 loss per share (vs US$0.15 loss in 3Q 2021)

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Ekso Bionics Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.10 loss in 2Q 2021)

Ekso Bionics Holdings, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Ekso Bionics Holdings, Inc. Receives FDA Clearance to Market Its Eksonr(Tm) Robotic Exoskeleton for Use with Multiple Sclerosis Patients

Ekso Bionics Holdings, Inc. Announces Chief Financial Officer Changes

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 09, 2022

First quarter 2022 earnings released: US$0.36 loss per share (vs US$0.34 loss in 1Q 2021)

Ekso Bionics Holdings, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Ekso Bionics Holdings, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.30 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$1.88 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.44 loss in 1Q 2020)

Director has left the company

Full year 2020 earnings released: US$2.21 loss per share (vs US$2.53 loss in FY 2019)

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 10, 2021

Ekso Bionics Holdings, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €10.50

Ekso Bionics Holdings, Inc. Announces Resignation of Ted Wang as Member of the Board of Director

New 90-day high: €6.40

Ekso Bionics Holdings, Inc. Appoints Charles Li to its Board of Directors

New 90-day high: €6.35

New 90-day high: €5.00

New 90-day low: €3.58

Third-quarter earnings released: Revenue beats expectations

Third quarter earnings released

Ekso Bionics Holdings, Inc. Announces EGM Builders as First Customer to Adopt Evo Technology

New 90-day low: €3.60

Ekso Bionics Holdings, Inc. to Report Q2, 2020 Results on Jul 30, 2020

Ekso Bionics Holdings, Inc.(NasdaqCM:EKSO) dropped from Russell Microcap Growth Index

マネジメント基準チェック /44